Clay Siegall: The Brain Behind Seattle Genetics

Seattle Genetics is a biotechnology company founded in 1998 and based out of Seattle, Washington. The company is focused on treating cancer through the development and use of antibody-based therapies. It has been recognized by several organizations for contributions to medicine and technology. The company thrives on innovation and scientific excellence and is a leader in the field.

A large part of the company’s success can be attributed to the solid leadership of co-founder, President and Chief Executive Officer, Clay Siegall. Siegall is a scientist by trade earning his Bachelor’s in Zoology from the University of Maryland and later completing his Doctorate in Genetics. Prior to founding Seattle Genetics, he worked in pharmaceutical research at the National Cancer Institute.

In addition to his clinical knowledge, the young scientist also shows a great level of business acumen. In 2012, he was honored as Ernst and Young’s Pacific Northwest Entrepreneur of the Year and he has taken the reins when it comes to the company’s fundraising efforts. Under his direction, Seattle Genetics has raised more than $675 million dollars in capital from both private and public investors.

Under his leadership, Seattle Genetics has developed several oncology-focused strategic partnerships with leading biotech and pharaceutical companies across the globe. The company has also brought to life several antibody drug conjugate(ADC) collaborations. These relationships have allowed the company to expand and see continued growth. To date, there are over 20 ADCs in clinical development using Seattle Genetics technology to serve the needs of cancer patients.

In addition to the company’s financial and clinical success, Seattle Genetics has also emerged as a coveted workplace. The company boasts tremendous health and wellness benefits and stresses career development and training. One of their core values even centers on creating a great work environment. The company embraces innovation in the hopes that it leads to medical breakthroughs. The company employs over 650 people in the Greater Seattle Area.

Under the leadership and direction of Clay Siegall, Seattle Genetics is anticipated to continue its growth trajectory in the coming years. The company hopes to continue to develop medical phenomenons that will improve the lives of cancer victims across the globe.